Crovalimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | Complement component 5 (C5) |
| Clinical data | |
| Trade names | Piasky |
| Other names | crovalimab-akkz |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Subcutaneous, intravenous |
| Drug class | Complement inhibitor |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6430H9974N1726O2026S46 |
| Molar mass | 145349.34 g·mol−1 |
Crovalimab, sold under the brand name Piasky, is a monoclonal antibody used for the treatment of people with paroxysmal nocturnal hemoglobinuria. It is a complement component 5 (C5) inhibitor.
Crovalimab was approved for use in China in February 2024, in Japan in April 2024, in the United States in June 2024, and in the European Union in August 2024. It was developed and is marketed by Roche/Genentech.